Tumor growth control by oral trofosfamide in patients with metastatic breast cancer

Onkologie

Volumn 21, Issue 1, 1998, Pages 52-56

  Mross, K ^a,b   Ruther A ^a   Gierlich, T ^a   Unger, C ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b Klinik fur Internistische Onkologie   (Germany)

Author keywords

Metastatic breast cancer; Palliative chemotherapy Trofosfamide

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE ANTIBIOTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; MELPHALAN; METHOTREXATE; MITOXANTRONE; NAVELBINE; THIOTEPA; TROFOSFAMIDE; VINCRISTINE;

ADULT; AGED; ALOPECIA; ARTICLE; BREAST CANCER; CANCER INHIBITION; COST BENEFIT ANALYSIS; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOPENIA; MAJOR CLINICAL STUDY; NAUSEA; NEPHROTOXICITY; QUALITY OF LIFE; THROMBOCYTOPENIA; VOMITING;

EID: 0031946008     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000026777     Document Type: Article

References (19)

1. Possinger K, Wilmans W: Palliative Therapieführung zur Hemmung der Tumorprogression bei Patientinnen mit metastasierten Mammakarzinomen. Internist 1993;34:340-350.
2. Hayes DF, Henderson C, Shapiro CL: Treatment of metastatic breast cancer: Present and future prospects. Semin Oncol 1995;22:5-21.
3. Hauser PH: Unproven methods in cancer treatment. Curr Opin Oncol 1993;5:646-654.
4. Ruther A, Holzer S: Unkonventionelle Therapie-Ansätze des Mammakarzinoms. Klinikarzt 1996;25: 236-242.
5. Brock N: Oxazaphosphorine cytotatics: Past - present - future Cancer Res 1989;49:1-7.
6. Boos J, Küpker F, Blaschke G, Jürgens H: Trofosfamide metabolism in different species - Ifosfamide is the predominant metabolite Cancer Chemother Pharmacol 1993;33:71-76.
7. Smith G, Henderson C: New treatments for breast cancer. Semin Oncol 1996;23 506-528
8. Boddy AV, Proctor M, Simmonds D, Lind MJ, Idle JR: Pharmacokinetics, metabolism and clinical effect of ifosfamide in breast cancer patients. Eur J Cancer 1995;31.69-76.
9. Overmoyer BA: Ifosfamide in the treatment of breast cancer. Semin Oncol 1996,23:38-41
10. Ingle JN, Krook JE, Mailliard JA, Hartmann LC, Wieand HS Evaluation of ifosfamide plus mesna as first-line chemotherapy in women with metastatic breast cancer. Am J Clin Oncol 1995,18.498-501.
11. Becher R, Kloke O, Hyungs J, Hartwich G, Bartels H, Szanto J, Wolf E, Elliger HJ, Halabi S, Rieche K, Hering KG, Ohl S, DeDycker R, Huhn R, Hofeler H, Pielken HJ, Hawig I, Hirche H, Seeber S. Epirubicin and ifosfamide in metastatic breast cancer. Semin Oncol 1996;23:28-33.
12. Lewis LD, Fitzgerald DL, Harper PG: Fractionated ifosfamide therapy produces a time-dependent increase in ifosfamide metabolism Br J Clin Pharm 1990;30:725-732
13. Goeren MP, Wright RK, Pratt CB: Dechloroethylation of ifosfamide and neurotoxicity. Lancet 1986; ii: 1219-1220.
14. Wagner T, Drings P: Pharmacokinetics and bioavailability, in Brade WP (ed): Ifosfamide in Tumour Therapy Contrib Oncol. Basel, Karger, 1987, vol 26, pp 53-59.
15. Scheef W, Exss R, Schnitker J, Soemer G: Trofosfamide in high dosage in mammary carcinoma. Krankenhausarzt 1984;57:935-942
16. Albrecht M, Kleinhauf-Houken A, Trams G, Thomsen K: 5 years experiences with adjuvant chemotherapy in primary breast cancer. Geburtshilfe Frauenheilk 1984;44:550-556
17. Gunsilius E, Eichelmann A, Gastl G, Mross K, Unger C: Advanced malignancies treated with oral trofosfamide: Results of a two year period Ann Oncol 1996;7(suppl 5):142.
18. Salminen E, Nikkanen V, Lindholm Palliative chemotherapy in non-Hodgkin's lymphoma. Oncology 1997;54:108-111.
19. Wist E, Risberg T: Trofosfamide in non-Hodgkin's lymphoma: A phase II study. Acta Oncol 1991,30. 819-821.